PRO-COG: Cognition Evolution and MRI Markers in PPMS Patients on 2 Years
Study Details
Study Description
Brief Summary
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease. Cognitive disorders frequency in MS is estimated between 40 and 60%. Cognitive impairment affects quality of life and vocational status in MS patients.
Until recently, little information was available on the cognitive dysfunction and their evolution that occur in primary progressive multiple sclerosis (PPMS) as compared with relapsing-remitting MS (RRMS). In PPMS pathological studies have shown the importance of cortical demyelination and meningeal inflammation suggesting that the GM alteration could play a major role in the cognitive impairment in this phenotype. The cognitive evolution and the brain tissue alteration at the origin of these difficulties remain poorly understood in PPMS. The use of new techniques for morphological and functional MRI can study the contribution of diffuse White Matter (WM) alteration (probably through disconnexion of relevant network) and diffuse Grey matter (GM) alterations in the cerebral cortex and other structures (the hippocampi, the cerebellum, and the thalami) in cognitive impairment in PPMS patients and on their evolution.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: patient PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011) |
Other: Clinical assessment
Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
Other: Ecological evaluation
Virtual reality task and Actual reality
Other: Neuropsychological evaluation
cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Other: Psychological evaluation
questionnaires for depression, anxiety and fatigue
Device: MRI Evaluation
morphological MRI and resting state functional MRI (fMRI)
|
| Active Comparator: Control 40 Healthy controls |
Other: Ecological evaluation
Virtual reality task and Actual reality
Other: Neuropsychological evaluation
cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
Other: Psychological evaluation
questionnaires for depression, anxiety and fatigue
Device: MRI Evaluation
morphological MRI and resting state functional MRI (fMRI)
|
Outcome Measures
Primary Outcome Measures
- Change of composite z cognitive score based on individual neuropsychological scores [At baseline (day 0) and at 24 months from baseline]
The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time (baseline and 2 years). Individual neuropsychological scores included in composite z cognitive score : the Alertness subtest, the divided attention subtest and the visual-scanning subtest from the TAP, The Symbol-digit-modalities-test, the Paced-Auditory-Serial-Addition-Test 3s, reversed span, the Stroop test, the Verbal fluency, Trail Making test, the California Verbal memory learning test and the Brief visual memory test -revised
Secondary Outcome Measures
- Correlation of composite z cognitive score and ecological score with MRI parameters reflecting grey and white matter integrity and anatomic/functional connectivity [At baseline (day 0) and at 24 months from baseline]
The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time. The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.
- Change of composite z cognitive score based on individual neuropsychological scores [At baseline (day 0), at 12 months and at 24 months from baseline]
The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time.
- Changes of composite z ecological score based on individual ecological scores [At baseline (day 0), at 12 months and at 24 months from baseline]
The composite z cognitive score is the average of z individual cognitive scores. The score from each cognitive test is transformed into z-scores. Z-scores will be calculated for each cognitive score with the following formula: (patient's score - mean value of HC group matched for age, sex, and education level)/standard deviation of the matched HC for each evaluation time. The composite z ecological score is the average of z ecological scores of virtual reality task (Urban DailyCog©) and actual reality tests.
Eligibility Criteria
Criteria
Inclusion Criteria:
PATIENTS
-
Male or female;
-
Age ≥ 18 years;
-
PPMS diagnosis according to McDonald 2010 criteria;
-
Disease duration ≤ 15 years;
-
Native French speaking;
-
Being affiliated to health insurance;
-
Willing to participate and to sign informed consent.
HEALTHY CONTROLS
-
Male or Female;
-
Age ≥ 18 years;
-
Native French speaking;
-
Being affiliated to health insurance;
-
Willing to participate and to sign informed consent.
Exclusion Criteria:
PATIENTS
-
previous history of other neurological disease;
-
psychiatric comorbidity including severe depression according to DSM-IV;
-
alcohol or other addiction to toxic;
-
disabling visual or motor problems preventing participation to neuropsychological assessments;
-
change of psychotropic drug since less than one month;
-
contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body,claustrophobia or refusing MRI);
-
illiteracy, is unable to count or to read;
-
pregnant or breastfeeding women;
-
patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
HEALTHY CONTROLS
-
history of neurological disease;
-
family history of MS;
-
psychiatric comorbidity including severe depression according to DSM-IV;
-
alcohol or other toxic addiction;
-
psychotropic drugs; known cognitive complaint or neuropsychological affection;
-
prior neuropsychological testing with the same tests less than 6 months
-
contra-indication to MRI (pacemakers, aneurysm clips, artificial heart valves, ear implants, meta fragments or foreign objects in the eyes, skin or body, claustrophobia or refusing MRI);
-
illiteracy, is unable to count or to read;
-
pregnant or breastfeeding women;
-
person concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU de Bordeaux | Bordeaux | France | ||
| 2 | CHU de Limoges | Limoges | France | ||
| 3 | CHU de Poitiers | Poitiers | France |
Sponsors and Collaborators
- University Hospital, Bordeaux
- Roche Pharma AG
Investigators
- Principal Investigator: Aurélie RUET, Prof, CHU Bordeaux
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHUBX 2017/14